This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Poster On MiMedx EpiFix® Receives Highest Score At The Symposium On Advanced Wound Care (SAWC)

MARIETTA, Ga., Oct. 3, 2013 /PRNewswire/ --  MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that a poster detailing an EpiFix® case study received the award for the highest scoring abstract in the case study category at the recent Symposium on Advanced Wound Care ("SAWC").  In all, six posters chronicling the clinical effectiveness of EpiFix® were accepted for presentation at the recent SAWC.

The abstract titled A Long-term Follow-up Study of Chronic Diabetic Foot Ulcers Healed with Dehydrated Human Amniotic/Chorionic Membrane Allografts was recognized at the SAWC as the highest scoring poster abstract in the Case Study category. The authors honored at the SAWC for the winning abstract were Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS; and Donald E. Fetterolf, MD, MBA, FACP.

The five other posters presenting EpiFix® cases and studies were:
  • Clinical and Cost Effectiveness of Dehydrated Human Amniotic/Chorionic Membrane Allografts for the Treatment of Non-Healing Wounds.
  • Dehydrated Human Amniotic Membrane for the Treatment of Pressure Ulcers in Spinal Cord Injured Veterans: A Case Series.
  • Dehydrated Human Amnion/Chorion Membrane Tissue Graft for the Treatment of Intractable Ulceration: A Series of Extraordinary Outliers.
  • Use of Dehydrated Human Amniotic Membrane Allografts to Promote Healing in Patients with Refractory Non-Healing Wounds. 
  • Viable Indications for the Use of Human Amniotic Membrane Allograft: A Case Series .

The six poster abstracts presented results of treatment with EpiFix® for a wide range of applications, including the treatment of non-healing wounds, pressure ulcers in spinal cord injured veterans, diabetic foot ulcers and intractable ulceration. The poster abstracts presented case and study results that showed closure of multiple different types of non-healing wounds using EpiFix®.  In one poster abstract comparing EpiFix® with a competitor's human fibroblast derived dermal substitute, the study cases demonstrated an 82% reduction in cost of wound closure in non-healing wounds treated with EpiFix®. In another poster abstract, the case study examined the use of EpiFix® for the treatment of difficult intractable wounds and concluded that difficult wounds which did not heal after treatment with a payer approved amount of bioengineered skin substitute, even those wounds secondary to radiation, responded and healed with EpiFix® treatment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs